Get the Stockscreener App
3.85
7.54%
0.27
Kyverna Therapeutics Inc stock is traded at $3.85, with a volume of 632.41K.
It is up +7.54% in the last 24 hours and down -6.10% over the past month.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
See More
Previous Close:
$3.58
Open:
$3.66
24h Volume:
632.41K
Relative Volume:
1.41
Market Cap:
$166.50M
Revenue:
-
Net Income/Loss:
$-110.66M
P/E Ratio:
-1.2434
EPS:
-3.0963
Net Cash Flow:
$-97.76M
1W Performance:
+9.69%
1M Performance:
-6.10%
6M Performance:
+38.49%
1Y Performance:
-51.57%
1-Day Range:
$3.50
$3.9825
1-Week Range:
$3.27
$3.9825
52-Week Range:
$1.78
$8.78
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Name
Kyverna Therapeutics Inc
Sector
Industry
Phone
(510) 626-8331
Address
5980 HORTON STREET, EMERYVILLE
Compare KYTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
3.85 | 153.09M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-24 | Initiated | UBS | Buy |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Jul-03-24 | Initiated | H.C. Wainwright | Neutral |
| Mar-04-24 | Initiated | JP Morgan | Overweight |
| Mar-04-24 | Initiated | Leerink Partners | Outperform |
| Mar-04-24 | Initiated | Morgan Stanley | Overweight |
| Mar-04-24 | Initiated | Wells Fargo | Overweight |
View All
Kyverna Therapeutics Inc Stock (KYTX) Latest News
Kyverna Therapeutics Inc. Rebound Backed by Sentiment ShiftJuly 2025 Institutional & Precise Swing Trade Entry Alerts - newsyoung.net
Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026 - Benzinga
Is It Too Early to Call Recovery in Kyverna Therapeutics Inc.2025 Pullback Review & Technical Pattern Recognition Alerts - newsyoung.net
Will Volume Confirm Reversal in Kyverna Therapeutics Inc.2025 Fundamental Recap & Verified Momentum Stock Ideas - thegnnews.com
Kyverna Therapeutics Inc. Stages Intraday Comeback — Trend ChangeQuarterly Profit Summary & Comprehensive Market Scan Insights - newsyoung.net
William Blair Initiates Kyverna Therapeutics at Outperform - MarketScreener
William Blair initiates coverage on Kyverna Therapeutics stock with Outperform rating - Investing.com
Real time scanner hits for Kyverna Therapeutics Inc. explainedJuly 2025 Snapshot & AI Forecasted Entry/Exit Points - Newser
Measuring Kyverna Therapeutics Inc.’s beta against major indicesQuarterly Growth Report & Consistent Profit Trading Strategies - Newser
Leerink Partnrs Brokers Lower Earnings Estimates for KYTX - MarketBeat
What does recent volatility data suggest for Kyverna Therapeutics Inc.Long Setup & Real-Time Buy Signal Notifications - Newser
Kyverna Therapeutics Inc. Included in Top Momentum ScanJuly 2025 Movers & Safe Capital Preservation Plans - classian.co.kr
Analyzing drawdowns of Kyverna Therapeutics Inc. with statistical toolsSell Signal & Real-Time Buy Zone Alerts - Newser
FY2025 EPS Forecast for Kyverna Therapeutics Cut by Analyst - MarketBeat
Custom strategy builders for tracking Kyverna Therapeutics Inc.2025 Top Decliners & Reliable Entry Point Alerts - Newser
How to monitor Kyverna Therapeutics Inc. with trend dashboardsInflation Watch & Consistent Return Investment Signals - Newser
Is Kyverna Therapeutics Inc. stock reversal real or fakeJuly 2025 Catalysts & Entry and Exit Point Strategies - Newser
Can Kyverna Therapeutics Inc. recover in the next quarterJuly 2025 Short Interest & AI Enhanced Execution Alerts - Newser
Order flow analysis tools used on Kyverna Therapeutics Inc.2025 Breakouts & Breakdowns & Low Risk High Win Rate Picks - Newser
What institutions are buying Kyverna Therapeutics Inc. stock nowJuly 2025 Sector Moves & Real-Time Volume Surge Alerts - Newser
Kyverna Therapeutics Inc. stock momentum explainedQuarterly Earnings Report & High Conviction Buy Zone Alerts - Newser
Will a bounce in Kyverna Therapeutics Inc. offer an exitWeekly Trade Summary & Weekly High Return Forecasts - Newser
Is now a turning point for Kyverna Therapeutics Inc.July 2025 Drop Watch & Comprehensive Market Scan Insights - Newser
Kyverna Therapeutics (NASDAQ:KYTX) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Trend analysis for Kyverna Therapeutics Inc. this weekRate Hike & Breakout Confirmation Alerts - Newser
What is HC Wainwright’s Forecast for KYTX FY2025 Earnings? - Defense World
Can Kyverna Therapeutics Inc. outperform under higher oil pricesIPO Watch & AI Driven Stock Movement Reports - sundaytimes.kr
Will Kyverna Therapeutics Inc. continue its uptrendTake Profit & Low Drawdown Investment Ideas - Newser
Identifying reversal signals in Kyverna Therapeutics Inc.Weekly Trend Recap & Daily Profit Maximizing Trade Tips - Newser
Using Bollinger Bands to evaluate Kyverna Therapeutics Inc.Weekly Stock Analysis & Low Risk Profit Maximizing Plans - Newser
Leerink Partnrs Issues Pessimistic Outlook for KYTX Earnings - Defense World
Is Kyverna Therapeutics Inc. a Top Dividend Stock to Watch in 2025Weekly Trend Recap & Daily Profit Maximizing Trade Tips - Newser
Kyverna Therapeutics Inc. stock trend forecastJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - Newser
Published on: 2025-08-15 20:21:05 - Newser
Kyverna Therapeutics reports Q2 EPS (97c), consensus ($1.04) - MSN
How Efficient Is Kyverna Therapeutics Inc. at Controlling Operating Costs2025 Top Gainers & Scalable Portfolio Growth Methods - Newser
What’s the recovery path for long term holders of Kyverna Therapeutics Inc.2025 Performance Recap & Fast Entry High Yield Tips - Newser
Kyverna Therapeutics Advances CAR T-Cell Therapy Trials - The Globe and Mail
Price action breakdown for Kyverna Therapeutics Inc.July 2025 Volume & AI Driven Price Forecasts - Newser
Kyverna Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire
Why Kyverna Therapeutics Inc. stock attracts strong analyst attentionRisk Managed High Gain Trades - kangso.co.kr
How is Kyverna Therapeutics Inc. managing supply chain issuesTop Market Cap Performer Picks - newsyoung.net
Kyverna Appoints New CFO to Guide Next Growth Phase - MSN
Leading vs lagging indicators on Kyverna Therapeutics Inc. performanceStrong Buy Signal Summary with Entry Zone - Newser
Published on: 2025-08-10 18:27:32 - metal.it
Kyverna Therapeutics Inc. Breaks Losing Streak — Is the Trend ReversingDaily Smart Money Movement Monitor Activated - beatles.ru
Kyverna Therapeutics (KYTX) to Release Earnings on Monday - MarketBeat
Kyverna Therapeutics (KYTX) Expected to Announce Quarterly Earnings on Monday - Defense World
Kyverna Therapeutics Inc expected to post a loss of $1.04 a shareEarnings Preview - TradingView
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Kyverna Therapeutics Inc Stock (KYTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):